Literature DB >> 2677298

Phagocytosis of Cryptococcus neoformans by rat alveolar macrophages.

B Bolaños1, T G Mitchell.   

Abstract

A radiolabeling method was developed to investigate the interaction in vitro between Cryptococcus neoformans and Lewis rat alveolar macrophages (AM phi). AM phi were harvested by lung lavage, monolayers of adherent cells were established in wells of microtiter plates and [51Cr]-labeled yeast cells were added to the monolayers. After removal of extracellular yeasts, the adherent radioactivity associated with the AM phi was directly proportional both to the number of yeasts added and to the number of yeasts per AM phi as determined by microscopic examination of Giemsa-stained monolayers. Phagocytosis (attachment and/or ingestion) of radiolabeled C. neoformans by AM phi was a sensitive, quantitative and reproducible assay for the evaluation of the AM phi-C. neoformans interaction. AM phi were able to phagocytose encapsulated strains of C. neoformans. The extent of phagocytosis was inversely related to the capsule size. Normal rat serum (NRS) was an excellent source of opsonins for the ingestion. Inactivation of serum complement or depletion of C3 by affinity chromatography removed most of the opsonic activity of NRS. Specific antibodies against C. neoformans did not increase phagocytosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2677298

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN: 0268-1218


  27 in total

Review 1.  Role of phagocytosis in the virulence of Cryptococcus neoformans.

Authors:  Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2004-10

2.  Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection.

Authors:  Kirsten Nielsen; Gary M Cox; Anastasia P Litvintseva; Eleftherios Mylonakis; Stephanie D Malliaris; Daniel K Benjamin; Steven S Giles; Thomas G Mitchell; Arturo Casadevall; John R Perfect; Joseph Heitman
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  In vivo role of dendritic cells in a murine model of pulmonary cryptococcosis.

Authors:  Karen L Wozniak; Jatin M Vyas; Stuart M Levitz
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 4.  Cryptococcal interactions with the host immune system.

Authors:  Kerstin Voelz; Robin C May
Journal:  Eukaryot Cell       Date:  2010-04-09

5.  Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody.

Authors:  M F Miller; T G Mitchell; W J Storkus; J R Dawson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

6.  Benzothiourea Derivatives Target the Secretory Pathway of the Human Fungal Pathogen Cryptococcus neoformans.

Authors:  Sarah R Beattie; Nicholas J Schnicker; Thomas Murante; Kavitha Kettimuthu; Noelle S Williams; Lokesh Gakhar; Damian J Krysan
Journal:  ACS Infect Dis       Date:  2020-02-26       Impact factor: 5.084

7.  Hybridization probes for conventional DNA fingerprinting used as single primers in the polymerase chain reaction to distinguish strains of Cryptococcus neoformans.

Authors:  W Meyer; T G Mitchell; E Z Freedman; R Vilgalys
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

8.  Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses.

Authors:  H L Collins; G J Bancroft
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

9.  Differential activation of peritoneal cells by subcutaneous treatment of rats with cryptococcal antigens.

Authors:  José L Baronetti; Laura S Chiapello; Ana P Garro; Diana T Masih
Journal:  Clin Vaccine Immunol       Date:  2009-06-03

10.  Surfactant protein D increases phagocytosis of hypocapsular Cryptococcus neoformans by murine macrophages and enhances fungal survival.

Authors:  Scarlett Geunes-Boyer; Timothy N Oliver; Guilhem Janbon; Jennifer K Lodge; Joseph Heitman; John R Perfect; Jo Rae Wright
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.